TABLE 4.
Predictors of Severe COVID-19 Among Patients With Schizophrenia
| B | SE | Wald | df | Sig. | Exp(B) | 95% CI for Exp(B) | ||
|---|---|---|---|---|---|---|---|---|
| Lower | Upper | |||||||
| Sex | 4.511 | 2.138 | 4.452 | 1 | 0.035 | 9.105 | 1.378 | 60.14 |
| Age | 0.090 | 0.043 | 4.350 | 1 | 0.037 | 1.094 | 1.005 | 1.190 |
| Type of antipsychotic | ||||||||
| FGA use (reference category) | 3.348 | 2 | 0.187 | |||||
| SGA use | −0.602 | 1.855 | 0.105 | 1 | 0.746 | 0.548 | 0.014 | 2.077 |
| FGA + SGA use | 2.983 | 1.698 | 3.085 | 1 | 0.079 | 1.974 | 0.708 | 5.558 |
| BMI | −0.233 | 0.260 | 0.800 | 1 | 0.371 | 0.792 | 0.476 | 1.319 |
| Comorbidity index | 0.318 | 0.092 | 11.957 | 1 | 0.001a | 1.375 | 1.148 | 1.647 |
| CPZE dose of AP | 0.012 | 0.004 | 10.416 | 1 | 0.001a | 1.989 | 1.982 | 1.995 |
aSignificant after Bonferroni correction (p < 0.00833).